Comparative Pharmacology
Head-to-head clinical analysis: LO ZUMANDIMINE versus LO OVRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO ZUMANDIMINE versus LO OVRAL.
LO-ZUMANDIMINE vs LO/OVRAL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
LO-ZUMANDIMINE is a novel small molecule inhibitor of the mitogen-activated protein kinase (MAPK) pathway. It selectively binds to and inhibits the activity of MEK1 and MEK2, thereby blocking downstream phosphorylation of ERK1/2 and inhibiting cell proliferation in tumors with activated MAPK signaling.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release, primarily FSH and LH, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial receptivity.
Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutationOff-label: Investigational use in colorectal cancer with BRAF mutations
Prevention of pregnancyDysfunctional uterine bleedingHormonal contraception
10-20 mg orally once daily, titrated to 40 mg daily based on response and tolerability.
One tablet (30 mcg ethinyl estradiol, 0.3 mg norgestrel) orally once daily for 28-day cycle (21 active, 7 placebo).
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in adults with normal renal function. In elderly patients (>/=65 years) or those with creatinine clearance <30 mL/min, half-life extends to 20–28 hours, necessitating dose interval adjustment.
Norgestrel (levonorgestrel): 11-45 hours (mean ~24 hours); ethinyl estradiol: 7-21 hours (mean ~14 hours). Half-life increases slightly with repeated dosing due to saturable metabolism.
Primarily metabolized by CYP3A4 and CYP2C8 enzymes. Minor contributions from CYP1A2 and CYP2D6. Undergoes glucuronidation via UGT1A1.
Ethinyl estradiol is primarily metabolized by CYP3A4; norgestrel is metabolized via reduction and conjugation; both undergo first-pass metabolism.
Renal excretion accounts for 60% of total clearance (30% unchanged via glomerular filtration, 30% as inactive glucuronide conjugate). Biliary/fecal elimination contributes 35% (20% as parent drug, 15% as oxidative metabolites). The remaining 5% is eliminated via sweat and expired air.
Urine (50-60% as conjugated metabolites), feces (30-40% as metabolites), enterohepatic recirculation present.
94–97% bound primarily to serum albumin (binding site II), with minor binding to alpha-1-acid glycoprotein. Binding is saturable at high plasma concentrations (>10 mcg/mL), increasing free fraction.
Levonorgestrel: 97-99% (primarily to sex hormone-binding globulin, SHBG, and albumin); ethinyl estradiol: 97-98% (primarily to albumin, increases SHBG levels).
Volume of distribution is 1.2–1.8 L/kg, indicating extensive tissue distribution. The central compartment Vd is 0.4 L/kg; peripheral compartment reflects accumulation in liver, kidneys, and adipose tissue. Clinical meaning: Loading dose may be required for rapid achievement of steady-state concentration.
Levonorgestrel: 1.0-1.3 L/kg; ethinyl estradiol: 2.3-3.0 L/kg. Reflects extensive tissue distribution and binding.
Oral bioavailability is 70–80% due to first-pass hepatic metabolism (CYP3A4). Rectal suppository bioavailability is 60–70%. Intramuscular bioavailability is >95%. Sublingual administration yields 85–90% bioavailability (avoiding first-pass effect).
Oral: levonorgestrel ~100% (first-pass metabolism <10%), ethinyl estradiol 38-48% due to first-pass conjugation in gut wall and liver.
eGFR ≥30 mL/min: no adjustment; eGFR 15-29 mL/min: reduce dose to 10 mg daily; eGFR <15 mL/min: contraindicated.
No dosage adjustment required for mild to moderate impairment. Not recommended in severe renal impairment (eGFR <30 mL/min/1.73m²) due to limited data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 10 mg daily; Child-Pugh C: contraindicated.
Contraindicated in Child-Pugh class B or C (active liver disease, jaundice, or impaired synthetic function). Use discontinued if hepatic function deteriorates.
Children ≥6 years: 0.2 mg/kg/dose (max 10 mg) orally once daily; may increase to 0.4 mg/kg (max 20 mg) after 2 weeks.
Post-menarche adolescents: Same dosing as adults (30 mcg ethinyl estradiol/0.3 mg norgestrel daily). Not indicated pre-menarche.
Initiate at 10 mg orally once daily; maximum 20 mg daily. Monitor renal function and avoid in patients with eGFR <30 mL/min.
Not indicated for postmenopausal women. Higher risk of thromboembolism and cardiovascular events in women >40 years, especially if smoking or other risk factors.
WARNING: SERIOUS SKIN REACTIONS AND OCULAR TOXICITY. LO-ZUMANDIMINE can cause severe dermatologic adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Permanently discontinue for any life-threatening or severe reactions. Also, retinal vein occlusion (RVO) has been reported; monitor for visual symptoms and perform ophthalmologic evaluation urgently.
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use; risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes/day); women should be strongly advised not to smoke.
Monitor for skin toxicity; interrupt or discontinue based on severity. Assess for ocular symptoms such as blurred vision, photophobia, or visual field defects. Avoid concurrent use with strong CYP3A4 inhibitors or inducers. May impair fertility. Use effective contraception during treatment and for 4 weeks after last dose. Cautious use in patients with hepatic impairment.
Increased risk of thromboembolic disorders (e.g., MI, stroke, VTE); hepatic adenoma; risk of breast cancer; hypertension; gallbladder disease; impaired glucose tolerance; cholestatic jaundice; ocular lesions (e.g., retinal thrombosis); use in pregnancy; fluid retention; hereditary angioedema.
Hypersensitivity to LO-ZUMANDIMINE or any excipients. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine). Active severe infection.
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; hepatic adenoma or malignancy; cholestatic jaundice of pregnancy or jaundice with prior pill use; active liver disease; hypersensitivity to any component; cigarette smoking in women ≥35 years; uncontrolled hypertension; diabetes with vascular involvement; headaches with focal neurological symptoms; major surgery with prolonged immobilization.
Data Pending Review
Data Pending Review
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase drug levels. Take with food to reduce GI upset, but avoid high-fat meals which may decrease absorption.
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels via CYP3A4 inhibition, but clinical relevance is minimal with low-dose pills. Avoid using St. John's wort, which may decrease contraceptive efficacy.
First trimester: Increased risk of congenital anomalies including neural tube defects and cleft palate based on animal studies; human data insufficient. Second/third trimesters: Possible fetal growth restriction and oligohydramnios; avoid use unless maternal benefit outweighs risk.
First trimester: No increased risk of major malformations based on epidemiological studies. Second/third trimesters: Exposure may increase risk of fetal liver tumors (rare) and possibly cardiovascular malformations; contraindicated due to feminization of male fetus. Post-market reports: Possible association with neonatal jaundice, cholestasis, and transient hormonal effects.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in nursing infant; manufacturer recommends discontinuing breastfeeding or drug.
Contraindicated during breastfeeding due to potential adverse effects on milk production and infant hormonal balance. M/P ratio not established; ethinyl estradiol and norgestrel are excreted into human milk in small amounts but insufficient data on infant exposure.
No specific dose adjustment recommended; however, increased clearance in pregnancy may require dose titration based on therapeutic response. Monitor drug levels if available.
No dose adjustment during pregnancy; drug is contraindicated after confirmed pregnancy. Pregnancy-induced changes in pharmacokinetics (increased clearance, volume of distribution) may reduce efficacy, but use is not recommended.
Category C
Category C
LO-ZUMANDIMINE is a prodrug that requires activation by CYP3A4; avoid concurrent use with strong CYP3A4 inhibitors or inducers. Monitor for QT prolongation, especially in patients with electrolyte abnormalities or pre-existing cardiac conditions. Administer with a full glass of water to reduce esophageal irritation.
Lo/Ovral is a low-dose combined oral contraceptive containing ethinyl estradiol and norgestrel. Not recommended for use in women with BMI > 35 kg/m² due to increased thromboembolic risk. Advise consistent daily timing within a 3-hour window to maintain efficacy. Missed pill management: if one pill is missed >12 hours late, take missed pill and continue with next pill at normal time; if two or more pills are missed, take the most recent missed pill and use backup contraception for 7 days. Consider CYP3A4 inducers (e.g., rifampin, St. John's wort) that may reduce efficacy.
Take this medication exactly as prescribed, at the same time each day.Do not consume grapefruit or grapefruit juice while taking this drug.Report any signs of irregular heartbeat, dizziness, or fainting immediately.Swallow tablets whole; do not crush or chew.Store at room temperature away from moisture and heat.
Take one tablet daily at the same time every day.Do not skip pills; if you miss a pill, follow the missed pill instructions in the package insert.Use backup contraception (e.g., condoms) if you vomit or have severe diarrhea within 4 hours of taking a pill.Avoid smoking, especially if over 35 years old, as it increases risk of serious cardiovascular side effects.Tell your healthcare provider about all medications and supplements you take, as some may interfere with birth control effectiveness.Lo/Ovral does not protect against HIV or other sexually transmitted infections.Store at room temperature away from moisture and heat.